Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) was the recipient of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 1,065,214 shares, a growth of 27.1% from the February 26th total of 837,841 shares. Currently, 2.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 194,283 shares, the days-to-cover ratio is presently 5.5 days.

Wall Street Analysts Forecast Growth

ANL has been the subject of a number of research analyst reports. HC Wainwright upgraded shares of Adlai Nortye from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Friday, February 13th. Wall Street Zen upgraded Adlai Nortye to a “hold” rating in a research report on Saturday, March 7th. Leerink Partners assumed coverage on Adlai Nortye in a report on Friday, March 20th. They set an “outperform” rating and a $23.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Adlai Nortye in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $19.50.

Adlai Nortye Stock Performance

Shares of NASDAQ ANL opened at $6.46 on Monday. Adlai Nortye has a fifty-two week low of $0.88 and a fifty-two week high of $12.09. The company’s 50 day simple moving average is $7.77 and its 200 day simple moving average is $3.74.

About Adlai Nortye

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.